IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP) (PADIS TVP)
This study has been completed.
Sponsor:
University Hospital, Brest
Information provided by (Responsible Party):
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT00740493
First received: August 22, 2008
Last updated: January 11, 2017
Last verified: January 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of warfarin therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test; and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE after stopping anticoagulant therapy on a follow-up of 2 years.
| Condition | Intervention | Phase |
|---|---|---|
| Recurrent Venous Thromboembolism Idiopathic Deep Vein Thrombosis | Drug: warfarin Drug: placebo of warfarin | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Proximal Deep Vein Thrombosis: a Multicentre Double-Blind Randomized Controlled Trial. "PADIS-TVP" Study. |
Resource links provided by NLM:
Further study details as provided by University Hospital, Brest:
Primary Outcome Measures:
- symptomatic recurrent venous thromboembolism and serious bleedings [ Time Frame: validated standardized objective tests ]
Secondary Outcome Measures:
- mortality due to another cause than recurrent venous thromboembolism or serious bleeding [ Time Frame: medical report and death certificates ]
| Enrollment: | 104 |
| Study Start Date: | July 2007 |
| Study Completion Date: | January 2017 |
| Primary Completion Date: | January 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
18 months of active warfarin therapy
|
Drug: warfarin
18 months of warfarin therapy
|
|
Placebo Comparator: 2
18 months of placebo of warfarin
|
Drug: placebo of warfarin
18 months of placebo of warfarin therapy
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with a first episode of idiopathic proximal deep vein thrombosis who have been treated during 6 months (Plus or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.
Exclusion Criteria:
- Age > 18
- warfarin hypersensibility
- unwilling or unable to give writting informed consent
- distal deep vein thrombosis or pulmonary embolism
- Proximal deep vein thrombosis which was provoked by a reversible major risk factor
- major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)
- previous documented episode of proximale deep vein thrombosis or pulmonary embolism
- other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)
- patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation
- pregnancy
- women without contraception
- planned major surgery in the next 18 months
- ongoing cancer or cured cancer in less than 2 years
- serious bleeding risk (e.g.: gastric ulcer)
- platelet count less than 100 Giga/l
- Life expectancy less than 18 months
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00740493
Please refer to this study by its ClinicalTrials.gov identifier: NCT00740493
Locations
| France | |
| CHRU de Brest | |
| Brest, France, 29609 | |
| CHU de Grenoble | |
| Grenoble, France, 38043 | |
| Centre Hospitalier Pierre Le Damany | |
| Lannion, France, 22303 | |
| Centre Hospitalier de Bretagne Sud | |
| Lorient, France, 56322 | |
| Centre Hospitalier Universitaire de Nantes | |
| Nantes, France, 44093 | |
| AP HP Hôpital Hôtel Dieu | |
| Paris, France, 75004 | |
| Hôpital Européen Georges Pompidou | |
| Paris, France, 75015 | |
| CHU de POITIERS | |
| Poitiers, France, 86021 | |
| Centre Hospitalier de Cornouaille | |
| Quimper, France, 29000 | |
| CHU de Rennes | |
| Rennes, France, 35023 | |
| Centre Hospitalier de Saint Brieuc | |
| Saint Brieuc, France, 22023 | |
| Hôpital de Rangueil | |
| Toulouse, France, 31000 | |
| CHU de Tours | |
| Tours, France, 37000 | |
| Centre Hospitalier Intercommunal | |
| Vernon, France, 27200 | |
Sponsors and Collaborators
University Hospital, Brest
Investigators
| Principal Investigator: | Francis Couturaud, MD, PhD | EA3878, IFR148 |
More Information
| Responsible Party: | University Hospital, Brest |
| ClinicalTrials.gov Identifier: | NCT00740493 History of Changes |
| Other Study ID Numbers: |
RB06.019 PADIS TVP |
| Study First Received: | August 22, 2008 |
| Last Updated: | January 11, 2017 |
Keywords provided by University Hospital, Brest:
|
recurrent venous thromboembolism idiopathic deep vein thrombosis optimal duration of anticoagulation |
Additional relevant MeSH terms:
|
Thrombosis Thromboembolism Venous Thromboembolism Venous Thrombosis Embolism and Thrombosis |
Vascular Diseases Cardiovascular Diseases Warfarin Anticoagulants |
ClinicalTrials.gov processed this record on August 22, 2017